Pipeline Therapeutics Appoints Julie Iwashita as Vice President of Clinical Operations

Dec. 3, 2020 16:00 UTC



SAN DIEGO--(BUSINESS WIRE)-- Pipeline Therapeutics, a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, today announced the appointment of Julie Iwashita as the company’s Vice President of Clinical Operations. Ms. Iwashita brings more than 30 years of experience guiding global neurology and other clinical development programs through the U.S. Food and Drug Administration (FDA) and other global health authorities.

“I am delighted to welcome Julie to Pipeline Therapeutics to spearhead our clinical development efforts,” said Carmine Stengone, President & CEO of Pipeline Therapeutics. “Julie’s extensive experience in managing drug candidates through the clinic, across a variety of therapeutic areas, will benefit us greatly as we move our neuroregenerative candidates through clinical studies and assemble the data packages needed for eventual NDA submissions.”

“I am delighted to be joining the Pipeline team, just as the company’s lead program, PIPE-505 for sensorineural hearing loss, is progressing through a proof-of-concept Phase 1/2a study, and as PIPE-307 enters the clinic, both candidates with great potential to help patients with unmet medical needs,” said Ms. Iwashita. “I believe Pipeline Therapeutics is well-positioned to transform the current treatment of neurological disorders, based on its exciting and proprietary technology covering synaptogenesis, remyelination and axonal repair.”

Julie most recently served as Vice President of Clinical Operations for Cirius Therapeutics, a clinical-stage pharmaceutical company focused on the development of treatments for liver and metabolic diseases. Previously she served as Executive Director, Clinical Operations at Kodiak Sciences Inc., (NASDAQ: KOD). Prior to Kodiak, Julie served as Executive Director of Clinical Development at Laguna Pharmaceuticals and before that at Sorbent Therapeutics. Prior to Sorbent, Julie was Senior Director of Clinical Development at MAP Pharmaceuticals, Proteolix, Inc. and Affymax, Inc. (OTCMKTS: AFFY). Julie has served as a consultant for multiple private and public biotech companies exploring neurological disorders including age-related macular degeneration, spinal cord injury, and migraine headaches. She has also managed clinical programs at Genitope, Aviron, Amgen and Syntex in therapeutic areas including renal, cardiovascular, and oncology.

Julie holds a bachelor’s degree in human biology from Stanford University.

About Pipeline Therapeutics

Pipeline Therapeutics is a biopharmaceutical company focused on the development and commercialization of first-in-class small molecules for neuroregeneration, including synaptogenesis, remyelination and axonal repair. The company's lead clinical program, PIPE-505, is currently enrolling patients in a phase 1/2a study to treat sensorineural hearing loss (SNHL) associated with speech-in-noise disability. The company also has a portfolio of programs addressing a range of neurological disorders, including development candidate PIPE-307 which is focused on remyelination to treat multiple sclerosis. For more information, please visit www.pipelinetherapeutics.com.


Company Contact: 
Carmine Stengone 
President and CEO 

Investor Contact: 
Laurence Watts 


Source: Pipeline Therapeutics

Back to news